## Kyoung Ah Min

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2762368/publications.pdf

Version: 2024-02-01

430874 477307 48 966 18 29 citations g-index h-index papers 49 49 49 1332 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer's disease: mechanism and brain delivery. Journal of Pharmaceutical Investigation, 2022, 52, 195.	5.3	1
2	Measurement of Transcellular Transport Rates and Intracellular Drug Sequestration in the Presence of an Extracellular Concentration Gradient. Methods in Pharmacology and Toxicology, 2021, , 3-39.	0.2	0
3	Synergistic Effect of Growth Factor Releasing Polymeric Nanoparticles and Ultrasound Stimulation on Osteogenic Differentiation. Pharmaceutics, 2021, 13, 457.	4.5	2
4	BSA/Silver Nanoparticle-Loaded Hydrogel Film for Local Photothermal Treatment of Skin Cancer. Pharmaceutical Research, 2021, 38, 873-883.	3 <b>.</b> 5	19
5	BSA-Silver Nanoparticles: A Potential Multimodal Therapeutics for Conventional and Photothermal Treatment of Skin Cancer. Pharmaceutics, 2021, 13, 575.	4.5	32
6	In Vitro and In Vivo Evaluation of PEGylated Starch-Coated Iron Oxide Nanoparticles for Enhanced Photothermal Cancer Therapy. Pharmaceutics, 2021, 13, 871.	4.5	14
7	Combined Application of Prototype Ultrasound and BSA-Loaded PLGA Particles for Protein Delivery. Pharmaceutical Research, 2021, 38, 1455-1466.	3 <b>.</b> 5	2
8	Practical approaches on the long-acting injections. Journal of Pharmaceutical Investigation, 2020, 50, 147-157.	<b>5.</b> 3	32
9	Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. ACS Pharmacology and Translational Science, 2020, 3, 107-118.	4.9	18
10	Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity. Biomaterials, 2020, 257, 120250.	11.4	7
11	<p>ICG-Loaded PEGylated BSA-Silver Nanoparticles for Effective Photothermal Cancer Therapy</p> . International Journal of Nanomedicine, 2020, Volume 15, 5459-5471.	6.7	64
12	Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides. Toxins, 2020, 12, 313.	3.4	9
13	Development and characterization of a superabsorbing hydrogel film containing Ulmus davidiana var. Japonica root bark and pullulan for skin wound healing. Saudi Pharmaceutical Journal, 2020, 28, 791-802.	2.7	12
14	Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Pharmaceutics, 2020, 12, 159.	4.5	20
15	Development of 20(S)-Protopanaxadiol-Loaded SNEDDS Preconcentrate Using Comprehensive Phase Diagram for the Enhanced Dissolution and Oral Bioavailability. Pharmaceutics, 2020, 12, 362.	4.5	9
16	Preparation and Characterization of Tenofovir Disoproxil-Loaded Enteric Microparticle. Journal of Nanoscience and Nanotechnology, 2020, 20, 5796-5799.	0.9	1
17	Potential Albumin-Based Antioxidant Nanoformulations for Ocular Protection against Oxidative Stress. Pharmaceutics, 2019, 11, 297.	4.5	41
18	Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for the Treatment of Wet Age-Related Macular Degeneration. Pharmaceutics, 2019, 11, 561.	4.5	9

#	Article	IF	CITATIONS
19	Externally Controlled Cellular Transport of Magnetic Iron Oxide Particles with Polysaccharide Surface Coatings. Cell Biochemistry and Biophysics, 2019, 77, 213-225.	1.8	2
20	Evaluation of epithelial transport and oxidative stress protection of nanoengineered curcumin derivative-cyclodextrin formulation for ocular delivery. Archives of Pharmacal Research, 2019, 42, 909-925.	6.3	26
21	Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect. Drug Development and Industrial Pharmacy, 2019, 45, 895-904.	2.0	4
22	Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy. Journal of Drug Targeting, 2019, 27, 950-958.	4.4	15
23	Preparation, Characterization, and In Vitro Release of Chitosan-Ecabet Electrolyte Complex for the Mucosal Delivery. Journal of Nanoscience and Nanotechnology, 2019, 19, 640-645.	0.9	3
24	Enhanced Solubility, In-Vitro Dissolution and Lipase Inhibition of a Self-Nanoemulsifying Drug Delivery System Containing Orlistat. Journal of Nanoscience and Nanotechnology, 2019, 19, 634-639.	0.9	5
25	Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations. Journal of Pharmaceutical Investigation, 2019, 49, 215-228.	5.3	28
26	Cell-penetrating peptide-based non-invasive topical delivery systems. Journal of Pharmaceutical Investigation, 2018, 48, 77-87.	5.3	21
27	Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance. International Journal of Nanomedicine, 2018, Volume 13, 7095-7106.	6.7	20
28	Flurbiprofen-Loaded Solid SNEDDS Preconcentrate for the Enhanced Solubility, In-Vitro Dissolution and Bioavailability in Rats. Pharmaceutics, 2018, 10, 247.	4.5	22
29	Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy. Archives of Pharmacal Research, 2018, 41, 594-616.	6.3	20
30	Molecular tumor targeting of gelonin by fusion with F3 peptide. Acta Pharmacologica Sinica, 2017, 38, 897-906.	6.1	30
31	Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment. International Journal of Pharmaceutics, 2017, 524, 101-110.	5.2	12
32	Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy. Archives of Pharmacal Research, 2017, 40, 1094-1104.	6.3	16
33	Human Airway Primary Epithelial Cells Show Distinct Architectures on Membrane Supports Under Different Culture Conditions. Cell Biochemistry and Biophysics, 2016, 74, 191-203.	1.8	14
34	Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity. Pharmaceutical Research, 2016, 33, 2218-2228.	3.5	24
35	Iron casein succinylate-chitosan coacervate for the liquid oral delivery of iron with bioavailability and stability enhancement. Archives of Pharmacal Research, 2016, 39, 94-102.	6.3	17
36	Construction and characterization of gelonin and saporin plasmids for toxic gene-based cancer therapy. Archives of Pharmacal Research, 2016, 39, 677-686.	6.3	9

#	Article	IF	CITATIONS
37	Functional and cytometric examination of different human lung epithelial cell types as drug transport barriers. Archives of Pharmacal Research, 2016, 39, 359-369.	6.3	11
38	Recombinant TAT-gelonin fusion toxin: Synthesis and characterization of heparin/protamine-regulated cell transduction. Journal of Biomedical Materials Research - Part A, 2015, 103, 409-419.	4.0	26
39	Cellâ€penetrating peptides: Achievements and challenges in application for cancer treatment. Journal of Biomedical Materials Research - Part A, 2014, 102, 575-587.	4.0	111
40	Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels. Biopharmaceutics and Drug Disposition, 2014, 35, 15-32.	1.9	10
41	Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. Journal of Controlled Release, 2014, 194, 197-210.	9.9	49
42	Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. Journal of Controlled Release, 2013, 172, 169-178.	9.9	35
43	Pulsed Magnetic Field Improves the Transport of Iron Oxide Nanoparticles through Cell Barriers. ACS Nano, 2013, 7, 2161-2171.	14.6	49
44	The Extracellular Microenvironment Explains Variations in Passive Drug Transport Across Different Airway Epithelial Cell Types. Pharmaceutical Research, 2013, 30, 2118-2132.	3.5	9
45	Pulmonary Administration of a Water-Soluble Curcumin Complex Reduces Severity of Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 280-287.	2.9	42
46	Transcellular Transport of Heparin-coated Magnetic Iron Oxide Nanoparticles (Hep-MION) Under the Influence of an Applied Magnetic Field. Pharmaceutics, 2010, 2, 119-135.	4.5	16
47	Improved gene expression pattern using Epstein–Barr virus (EBV)-based plasmid and cationic emulsion. Biomaterials, 2005, 26, 1063-1070.	11.4	11
48	Prolonged gene expression in primary porcine pancreatic cells using an Epstein–Barr virus-based episomal vector. Biochemical and Biophysical Research Communications, 2003, 305, 108-115.	2.1	17